You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀(01952.HK)認購I-Mab的1585萬股美國預託股份

格隆匯8月1日丨雲頂新耀(01952.HK)公告,2025年8月1日,公司認購I-Mab(一間於納斯達克全球市場上市的公司,股份代號爲“IMAB”)的15,846,154股美國預託股份(ADS)(每十(10)股ADS相當於23股普通股),每股ADS爲1.95美元(相當於約每股ADS15.3港元)。

認購事項的總代價爲30.9百萬美元。認購事項完成後,公司將合共持有15,846,154股ADS及6,078,571股普通股,佔緊隨認購事項結束後經配發及發行ADS擴大後I-Mab已發行股本總額約16.1%。

I-Mab爲一間總部設於美國的全球性生物科技公司,專注於研發針對癌症治療的精準免疫腫瘤學藥物。I-Mab目前有三項處於臨牀階段的管線產品,包括Givastomig(Claudin 18.2 x 4-1BB雙特異性抗體)、Ragistomig(PD-L1 x 4-1BB雙特異性抗體)及Uliledlimab(CD73抗體)。

董事會認爲,認購事項可確認I-Mab於臨牀轉化方面的獨特能力,特別是在美國,與公司於亞洲地區的強大影響力,以及於差異化4-1BB技術平臺及雙特異性抗體研發管線方面的優勢,形成互補及協同效應,並與公司於mRNA癌症疫苗方面的現有投資相得益彰。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account